Skip to main content

Table 3 Association between CSA and patient variables

From: Effect of routine vs on-demand nebulization of acetylcysteine with salbutamol on accumulation of airway secretions in endotracheal tubes: substudy of a randomized clinical trial

Variable Univariate P value Multivariate P value
estimate with 95% CI estimate with 95% CI
Randomization group − 1.1 (− 5.1 to 3.0) 0.60 1.3 (− 4.6 to 7.3) 0.65
Duration of mechanical ventilation − 0.2 (− 0.5 to 0.1) 0.21 − 0.1 (− 0.6 to 0.3) 0.56
Reason for mechanical ventilation (direct pulmonary vs. indirect pulmonary) 1.6 (− 3.6 to 6.9) 0.54 5.1 (− 3.5 to 13.7) 0.24
Gender 2.8 (− 1.5 to 7.1) 0.19 3.1 (− 4.0 to 10.3) 0.39
APACHE II − 0.2 (− 0.5 to 0.2) 0.43 − 0.2 (− 0.7 to 0.2) 0.35
Tube diameter − 1.2 (− 5.4 to 3.0) 0.58 0.5 (− 6.9 to 7.9) 0.89
Age − 0.0 (− 0.2 to 0.1) 0.71   
History of diabetes 0.5 (− 4.7 to 5.8) 0.84   
History of CVD − 2.0 (− 6.9 to 3.0) 0.42   
History of pulmonary disease 1.6 (− 5.7 to 8.9) 0.66   
BMI − 0.0 (− 0.4 to 0.3) 0.98   
Total amount of acetylcysteine nebulizations − 0.0 (− 0.1 to 0.1) 0.77   
Total amount of salbutamol nebulizations − 0.0 (− 0.1 to 0.1) 0.91   
Acetylcysteine nebulizations per day − 0.1 (− 0.5 to 0.3) 0.64   
Salbutamol nebulizations per day − 0.0 (− 0.4 to 0.3) 0.81   
Total amount of nebulizations per day − 0.1 (− 0.5 to 0.3) 0.69   
Amount of acetylcysteine nebulization days − 0.0 (− 0.3 to 0.3) 0.89   
Amount of salbutamol nebulization days 0.0 (− 0.3 to 0.3) 0.95   
Nebulizations days − 0.0 (− 0.3 to 0.3) 0.97   
Total amount of nebulizations − 0.0 (− 0.1 to 0.1) 0.79   
  1. CI, confidence interval; APACHE II, Acute Physiology and Chronic Health Evaluation II; CVD, cardio-vascular disease; BMI, body mass index